FIGURE 1

DIAGRAMATIC REPRESENTATION OF THE NORMAL MAMMALIAN CELL CYCLE

Fig. 2a

Fig. 2b

Fig. 3a

Fig. 3b

Fig. 3c

Fig. 4a

Fig. 4b

Fig. 4c

TABLE 1. The Distribution of Sex and Age of 100 Patients with A.L.F.

AGE	F	M	TOTAL
1-	2	3	5
11-	1		1
21-	3	5	8
31-	10	2	12
41-	16	7	23
51-	21	7	23
61-	20	1	21
71-	2		2
TOTAL	75	25	100

TABLE 2.

ACE Dosages 20580

	Patient		Dosage (cc/q4d) (minimum dose in cc that triggers blastogenesis)	
	No.	%	Range	Mean
Normal	47	47	0.1	0.1
Build up	37	37	0.15-1.0	0.3
Dilution	16	16	0.01-0.00001	0.05

TABLE 3.   The Distribution of Time of Therapy

Months	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	14	11	7	7	6	10	6	4	7	20

Average therapy time: 7.4 ± 3.8 months

Range: 2-16 months

TABLE 4.   The Distribution of Dosage of Therapy

Dosage (cc)	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	13	15	6	8	11	10	6	4	7	14

Average therapy dose: 6.44 ± 3.79 cc

Range: 2-25 cc

TABLE 5. Scale of Clinical Symptoms and Signs of
The Patient After ALF Treatment
(Severity)

Symptoms	Improvement		No Charge		Worsening		Total Patients
	No.	%	No.	%	No.	%	
Hypersensitive Reaction	63	63	33	33	1	1	100
Recurrent Infection	38	57	29	43	0	0	67
Fatigue	60	68	27	31	1	1	88
Lack of Concentration	43	54	36	46	0	0	79
Arthritis	19	44	23	54	1	2	43
G.I. Upset	29	40	43	60	0	0	72
Headache	28	44	33	53	2	3	64
Depression	42	58	30	42	0	0	72

TABLE 6.

Scale of Clinical Symptoms and Signs of The Patient After ALF Treatment (Frequency)

Symptoms	Improvement		No Charge		Worsening		Total Patients
	No.	%	No.	%	No.	%	
Hypersensitive Reaction	38	38	62	62	0	0	100
Recurrent Infection	26	39	41	61	0	0	67
Fatigue	38	43	50	57	0	0	88
Lack of Concentration	20	25	59	75	0	0	79
Arthritis	11	26	32	74	0	0	43
G.I. Upset	21	29	51	69	0	0	72
Headache	19	30	45	70	0	0	64
Depression	30	42	42	58	0	0	72

TABLE 7.   The Changes of T&B Profile of 92 Patients Treated with ALF

	TOTAL LYMPHOCYTES	T_{11}	T_4	T_8	T_4/T_8	B_1
BEFORE	2112±632	1624±457	930±45	439±58	2.3±0.8	188±102
AFTER	2232±678 *	1634±544	1027±297 **	478±189 **	1.3±0.4	171±120

wrong (handwritten)

n = 92   * $p<0.05$ ** $p<0.01$

TABLE 8. T Lymphocyte Subsets of 92 Patients After ALF Treatment

	TOTAL LYMPHOCYTES		T_{11}		T_4		T_8	
	NO.	%	NO.	%	NO.	%	NO.	%
INCREASE	52	57	41	46	53	58	55	60
DECREASE	40	43	51	54	39	42	37	40
P	<0.05		>0.05		<0.05		<0.01	

TABLE 9.

CMI Results with ALF Effect

CMI Scores (Number and Size, $\bar{x} \pm$ SD)

NO. PATIENTS	BEFORE ALF	AFTER ALF	P
78	5.46 ± 5.81	9.28 ± 7.25	<0.001

CMI Positive Score
(Number and Size) After ALF

	NO. PATIENTS	%	P
INCREASE	58	74	<0.001
NO CHANGE	9	12	
DECREASE	11	14	

The Relationship Between CMI and Clinical Symptom and Sign Improvement

	IMPROVEMENT NO.	%	NO IMPROVEMENT NO.	%	P
CMI INCREASE	56	72	2	3	<0.001
CMI NO CHANGE & DECREASE	14	18	6	8	

TABLE 10.   Side Effects of ALF - $^{c}5^{m}05^{c}1^{m}-^{c}1^{m}29^{m}20^{m}06^{m}0$ (5% of Patients Can Not Tolerate ALF)

1. PAIN AND IRRITATION IN THROAT, BURNING IN THE EYES

2. NAUSEA

3. CHEST TIGHTNESS AND HEART PALPITATION

4. FLU-LIKE SYMPTOMS, HEADACHE, FATIGUE, CHILL

5. INCREASE IN FOOD AND ODOR SENSITIVITY

Table 11

190 Patients with ALF

	No.	%
Female	131	69
Male	59	31
Age:	2-76 years old	
Mean:	46.8 years old	

Table 12

ALF Dosage

	Patient		Dosage (cc/q4d) (minimum dose in cc that triggers blastogenesis)
	No.	%	Range
Normal	88	46	0.1 (1:10)
Build up	84	44	0.15-1.0 (1:10)
Dilution	18	9	0.1 (1:20, $1:10^2$-$1:10^6$)

Table 13

The distribution of period of ALF therapy

Month	No. Patients	%
1-3	27	14.2
4-6	19	10.0
7-9	25	13.2
10-12	20	10.5
13-15	11	5.8
16-18	21	11.1
19-21	21	11.1
22-24	7	3.7
24-26	14	7.4
27-29	11	5.8
30-32	5	2.6
33-36	9	4.7

Average: 14.6 months (Range 1-37 months)

Table 19

The Distribution of dosage of ALF

Dosage (cc)	No. Patient	%
1-5	45	23.7
6-10	59	31.1
11-20	66	34.7
21-30	19	10
31-40	1	0.5
Total	190	100

Average: 11.27 (cc)
Range: 1-38 (cc)

Table 15

Scale of Clinical Symptoms and Signs of The C.S. Patient After ALF Treatment (Severity)

Symptoms	Improvement No.	%	No Changes No.	%	Worsening No.	%	Total Patients
Hypersensitive Reaction	51	56.7	33	36.7	6	6.7	90
Recurrent Infection	33	50.8	27	41.5	5	7.7	65
Fatigue	58	71.6	17	20.99	6	7.4	81
Lack of Concentration	42	57.5	29	39.7	2	2.7	73
Arthritis	20	44.4	22	48.9	3	6.7	45
G.I.Upset	32	44.4	33	45.8	7	9.7	72
Headache	30	40.5	38	51.4	6	8.1	74
Depression	44	63.8	22	31.9	3	4.3	69

Table 16

Scale of Clinical Symptoms and Signs of The Patient After ALF Treatment (frequency)

Symptoms	Improvement No.	%	No Changes No.	%	Worsening No.	%	Total Patients
Hypersensitive Reaction	28	36.4	46	59.7	3	3.9	77
Recurrent Infection	27	46.6	27	46.6	4	6.9	58
Fatigue	36	47.4	37	48.7	3	3.9	76
Lack of Concentration	23	33.8	43	63.2	2	2.9	68
Arthritis	13	32.5	24	60.0	3	7.5	40
G.I.Upset	23	37.1	35	56.5	4	6.5	62
Headache	24	38.1	34	54.0	5	7.9	63
Depression	34	54.8	26	41.9	2	3.2	62

Table 17

T&B Lymphocytes Parameters Changes After ALF

	(N)	Before (mean+SE)	After
WBC	25	4180±404.1**	4828±1164.6
Lymphs	34	1350 ±225.1**	1573.2±448.2
T11	32	989.4±198.1**	1182.6±331.2
T4	30	518.2±107.2**	689.5 ±200.1
Ratio of T4/T8	46	3.62± 0.99**	2.71± 1.04
T8	52	248.6±63.3**	354.3 ±124.9
B4	35	54.8±17.0**	121.3±78.7

**--P<0.01 (Change compared with before ALF therapy)

Table 18

T&B Lymphocytes parameters improvement after ALF

	Patients No.	Improved No.	(%)
WBC	25	18	72%
Lymphs	34	25	74%
T11	32	21	66%
T4	30	24	80%
Ratio of T4/T8	46	37	80.4%
T8	52	40	76.9%
B4	35	27	77%

Table 19

CMI Improvements of 93 Patients with ALF

	Total No. of Antigen Responses
Increase	247*
Decrease	171
No change	233
Total	651

* P<0.001 compared with decrease

Table 20

Diagnosis

	No.	%
Chemical sensitivity	127	67
Food Sensitivity	106	56
Inhalant Sensitivity	84	44
EMF Sensitivity	9	5

Table 21

Diagnosis

	No.	%
N.S	104	54.7
C.V	53	27.9
G.I	59	31.1
G.U	15	7.9
M.S	107	56.3
EYE	4	2.1
Respiratory	87	45.8
Skin	22	11.6
Endocrine	24	12.6
Immune dysregulation	99	52.1
Chronic infectioin	42	22.1
Implant	7	3.7
Parasite	3	1.6
Carcinoma	3	1.6
Candidosis	8	4.2
HIV positive	1	0.5

TABLE 22

50 Year Old White Female
HIV Positive

0.1cc every 4 doses

	CMI before −1	CMI after 3
WBC −	3,500	10,000
T_{11}	964	1359
$T_{11\%}$	54	73%
T_4	149	750
$T_{4\%}$	8%	40%
T_8	464	875
$T_{8\%}$	26	47%
T_4/T_8	.17	1.62
B	36	93
B%	2	5%

Sx-fatigue,   Energy
    neuropathy   − gone
Stomach Pain   − gone
Non healing toe − gone
Lesion for 2 yrs. − gone

Took ALF for 5 months, then stopped
All Sx exacerbated for 3 weeks.
Restarted ALF and Sx disappeared

Table 23

B: Before ALF
A: After ALF

PATIENTS WITH CANCER & ALF

	46 y F Breast Cancer		59 y F Breast Cancer		84 y F Leukemia		67 y F para-thyroid tumor		42 y F Breast Cancer		63 y F Left Breast Mastectomy		23 y M Osteo-genic Sarcoma	
	3/1/95 9/3/96		6/1/95 7/21/95		10/20/94 2/7/95		3/25/96 1/9/97		10/10/94 5/30/95		10/31/96 1/10/97		4/8/96 9/24/96	
	0.1cc 0.2cc 90 doses		0.1cc		0.1cc		$1:10^1$-1:10 0.1cc		0.1cc		0.1cc		0.1cc	
			40		60		130		90		70		50	
	B	A	B	A	B	A	B	A	B	A	B	A	B	A
Tetanus	3		0				30		5		0			
Diphtheria	4		0				6		4		0			
Streptococcus	0		0				0		0		0			
Tuberculin	0		0				0		0		0			
Control	0		0				0		0		0			
Candida	0		0				0		0		0			
Trichophyson	0		0				0		0		0			
Proteus	4		4				0		4		0			

	46 Y F Breast Cancer B	46 Y F Breast Cancer A	59 Y F Breast Cancer B	59 Y F Breast Cancer A	84 Y F Leukemia B	84 Y F Leukemia A	66 Y F Para-thyroid tumor B	66 Y F Para-thyroid tumor A	42 Y F Breast Cancer B	42 Y F Breast Cancer A	63 Y F Left Breast B	63 Y F Left Breast A	23 Y M Osteogenic Sarcoma B	23 Y M Osteogenic Sarcoma A
WBC	5100	6900, 4300↓, 4200↓				22300↑	7000		4700	5300, 4500	6700			
Lymphocytes	2550	2277, 1720, 1848				15387↑	2590		1833	1431, 1305	2412			
$Ly\%$	50	33, 40, 44				69	37		39	27, 29	36			
T_{11}	1734	1867, 1066↓, 1478				4923↑	1868		1448	1188, 861	1787			
$T_{11}\%$	68	82, 62, 80				32	76		79	83, 66	72			
T_4	944	1002, 378↓, 832				2308↑	1606		733	587, 469	724			
$T_4\%$	37	44, 22↓, 45				15↓	62↑		40	41, 36	30			
T_8	612	433, 482, 591				2616↑	544		495	329, 235	699			
$T_8\%$	24	19, 28, 32				17	21		27	21, 18	29			

						1.8	
T₄/T₁	15	2.32 0.79↓ 1.41		0.9↓	2.95↑	1.5	1.03
						2	
B₄	332	205 120 92		1848↑	104	155	172 184
							241
B₁⁸	13	9 7 5		12	4	9	12
						8	10

S: Severity
F: Frequency

		A		A
Allergic	S	↑		0
	F	↑		0
Headaches	S	0		0
	F	0		0
Recurrent Infection	S	↑		0
	F	↑		0
Fatigue	S	↑		0
	F	↑		0
Difficulty Concen- tration	S	↑		0
	F	0		0
Arthritis	S	↑		0
	F	↑		0
GI Upset	S	↑		0
	F	↑		0
Depression	S	↑		0
	F	↑		0